NTRK1 and non-small cell lung carcinoma: Sunitinib is a clinically approved small molecule drug that exerts anti-angiogenic and anti-proliferative activity against NSCLC through the inhibition of certain receptor tyrosine kinases, such as the platelet-derived growth factor receptors (PDGFRs), the vascular endothelial growth factor receptors (VEGFRs), and the stem-cell factor receptor KIT [22–25].